Methods for detecting predisposition to cancer at the MTS gene

• US 5,989,815 A
• Filed: 04/29/1997
• Issued: 11/23/1999
• Est. Priority Date: 03/18/1994
• Status: Expired due to Term

• Current Assignee: University of Utah Research Foundation (State of Utah)
• Original Assignee: Myriad Genetics, University of Utah Research Foundation (State of Utah)
• Inventors: Cannon-Albright, Lisa A., Skolnick, Mark H., Kamb, Alexander
• Primary Examiner(s): Marschel, Ardin H.
• Assistant Examiner(s): Riley, Jezia
• Application Number:
  US08/848,251
• Time in Patent Office: 938 Days
• Field of Search: 536/23.1, 435/6, 435/91.1, 435/91.2, 514/1, 514/44
• US Class Current: 435/6.16
• CPC Class Codes: A01N 61/00 Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
• CPC Class Codes: C07H 21/02 with ribosyl as saccharide radical
• CPC Class Codes: C12Q 1/68 involving nucleic acids
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

The present invention relates to somatic mutations in the Multiple Tumor Suppressor (MTS) gene in human cancers and their use in the diagnosis and prognosis of human cancer. The invention further relates to germ line mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin'"'"'s lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.

Claims

1. A method for diagnosing a polymorphism associated with predisposition for cancer selected from the group consisting of melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin'"'"'s lymphoma, chronic lymphocytic leukemia (CLL), and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum, in a human comprising:

detecting a germline alteration of a wild-type Multiple Tumor Suppressor gene or its expression products in a human sample wherein said Multiple Tumor Suppressor gene or said expression product is a nucleic acid or a polypeptide defined by any one of the group of SEQ ID NOs;

1-5, 13-16, 24 and 36, said alteration indicating a predisposition to at least one of said cancers.

2. The method of claim 1 wherein said Multiple Tumor Suppressor gene is Multiple Tumor Suppressor 1.

3. The method of claim 1 wherein said Multiple Tumor Suppressor gene is Multiple Tumor Suppressor 2.

4. The method of claim 1 wherein said Multiple Tumor Suppressor gene is Multiple Tumor Suppressor 1E1β

.

5. The method of claim 1 wherein said expression product is mRNA of Multiple Tumor Suppressor 1.

6. The method of claim 1 wherein said expression product is mRNA of Multiple Tumor Suppressor 2.

7. The method of claim 1 wherein said expression product is mRNA of Multiple Tumor Suppressor 1E1β

.

8. The method of claim 5 wherein the alteration of the wild-type Multiple Tumor Suppressor gene mRNA is detected by hybridization of the mRNA from said tissue sample to a Multiple Tumor Suppressor probe wherein said hybridization is performed under conditions in which said Multiple Tumor Suppressor probe will hybridize to altered Multiple Tumor Suppressor mRNA but not to wild-type Multiple Tumor Suppressor mRNA.

9. The method of claim 6 wherein the alteration of the wild-type Multiple Tumor Suppressor gene mRNA is detected by hybridization of the mRNA from said tissue sample to a Multiple Tumor Suppressor gene probe wherein said hybridization is performed under conditions in which said Multiple Tumor Suppressor probe will hybridize to altered Multiple Tumor Suppressor mRNA but not to wild-type Multiple Tumor Suppressor mRNA.

10. The method of claim 7 wherein the alteration of the wild-type Multiple Tumor Suppressor gene mRNA is detected by hybridization of the mRNA from said tissue sample to a Multiple Tumor Suppressor gene probe wherein said hybridization is performed under conditions in which said Multiple Tumor Suppressor probe will hybridize to altered Multiple Tumor Suppressor mRNA but not to wild-type Multiple Tumor Suppressor mRNA.

11. The method of claim 1 wherein the alteration is detected in a part of the regulatory region of the Multiple Tumor Suppressor gene, said part of the regulatory region being selected from the group consisting of nucleotides 1-866 of SEQ ID NO:

3, 1-334 of SEQ ID NO;

15 and 1-141 of SEQ ID NO;

13.

12. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by observing shifts in electrophoretic mobility of single-stranded DNA on non-denaturing polyacrylamide gels.

13. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by hybridization of a Multiple Tumor Suppressor gene probe to genomic DNA isolated from said tissue wherein said hybridization is performed under conditions in which said Multiple Tumor Suppressor probe will hybridize to altered Multiple Tumor Suppressor genomic DNA but not to wild-type Multiple Tumor Suppressor genomic DNA.

14. The method of claim 13 wherein the Multiple Tumor Suppressor gene probe hybridizes to an exon selected from the group consisting of nucleotides 867 to 1016 of SEQ ID NO:

3 and nucleotides 192 to 498 of SEQ ID NO;

4.

15. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by hybridization with a Multiple Tumor Suppressor allele-specific probe wherein said hybridization is performed under conditions in which said Multiple Tumor Suppressor allele-specific probe will hybridize to an altered Multiple Tumor Suppressor gene but not to a wild-type Multiple Tumor Suppressor gene.

16. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by amplifying all or part of the Multiple Tumor Suppressor gene in said tissue to produce an amplified sequence and sequencing the amplified sequence.

17. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by amplifying all or part of the Multiple Tumor Suppressor gene for a specific Multiple Tumor Suppressor allele.

18. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by molecularly cloning all or part of the Multiple Tumor Suppressor gene in said tissue to produce a cloned sequence and sequencing the cloned sequence.

19. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by identifying a mismatch between molecules (1) Multiple Tumor Suppressor gene genomic DNA or Multiple Tumor Suppressor mRNA isolated from said tissue and (2) a nucleic acid probe complementary to the human wild-type Multiple Tumor Suppressor region DNA, when molecules (1) and (2) are hybridized to each other to form a duplex under hybridization conditions which allow molecules with less than 100% complementarity to hybridize.

20. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by amplification of Multiple Tumor Suppressor gene sequences in said tissue and hybridization of the amplified sequences to nucleic acid probes which comprise wild-type Multiple Tumor Suppressor gene sequences.

21. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by amplification of Multiple Tumor Suppressor gene sequences in said tissue and hybridization of the amplified sequences to nucleic acid probes which comprise non-wild-type Multiple Tumor Suppressor gene sequences.

22. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by screening for a deletion mutation.

23. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by screening for a point mutation.

24. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by screening for an insertion.

25. The method of claim 1 wherein the alteration of the wild-type Multiple Tumor Suppressor gene is detected by in situ hybridization of the Multiple Tumor Suppressor gene with nucleic acid probes which comprise the Multiple Tumor Suppressor gene.

26. The method of claim 1 wherein the expression products are protein molecules.

27. The method of claim 26 wherein the alteration of wild-type Multiple Tumor Suppressor gene protein is detected by immunoblotting using antibodies which distinguish between altered Multiple Tumor Suppressor gene protein and wild-type Multiple Tumor Suppressor gene protein.

28. The method of claim 26 wherein the alteration of wild-type Multiple Tumor Suppressor gene protein is detected by a monoclonal antibody wherein said monoclonal antibody distinguishes between altered Multiple Tumor Suppressor gene protein and wild-type Multiple Tumor Suppressor gene protein.

29. The method of claim 26 wherein the alteration of wild-type Multiple Tumor Suppressor gene protein is detected by immunocytochemistry wherein said method utilizes an antibody or antibodies which distinguish between altered Multiple Tumor Suppressor gene protein and wild-type gene protein.

30. The method of claim 26 wherein the alteration of wild-type Multiple Tumor Suppressor gene protein is detected by assaying for binding interactions between Multiple Tumor Suppressor gene protein isolated from said tissue and a Cdk wherein the inability of a Multiple Tumor Suppressor gene protein to bind to a Cdk under conditions in which wild-type Multiple Tumor Suppressor gene protein binds to said Cdk indicates the presence of altered Multiple Tumor Suppressor gene protein.

31. The method of claim 30 wherein said Cdk is Cdk4.

32. The method of claim 26 wherein the alteration of wild-type Multiple Tumor Suppressor gene protein is detected by assaying for the inhibition of biochemical activity of a Cdk wherein a lack of inhibition or a decreased inhibition of said Cdk in an assay utilizing the Multiple Tumor Suppressor gene protein sample of interest as compared to an identical assay utilizing known wild-type Multiple Tumor Suppressor gene protein indicates the presence of altered Multiple Tumor Suppressor gene protein in said sample.

33. The method of claim 32 wherein said Cdk is Cdk4.

34. A method for confirming the lack of a predisposition for cancer at the Multiple Tumor Suppressor locus in a human, comprising:

detecting the wild-type Multiple Tumor Suppressor gene or its expression products in a human sample, wherein said Multiple Tumor Suppressor gene or said expression product is a nucleic acid or a polypeptide defined by any one of the group of SEQ ID NOs;

1-5, 13-16, 24 and 36, the presence of the wild-type gene or expression products indicating no predisposition to cancer at the Multiple Tumor Suppressor locus.